Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (3)

The Experiences of People Living With Peripheral Neuropathy in Kuwait-A Process Map of the Patient Journey


The Experiences of People Living With Peripheral Neuropathy in Kuwait-A Process Map of the Patient Journey

Maryam Alkandari et al. Pharmacy (Basel).


Peripheral neuropathy is a neurological disease characterised by pain, numbness, tingling, swelling or muscle weakness due to nerve damage, caused by multiple factors such as trauma, infections and metabolic diseases such as diabetes. In Kuwait 54% of the diabetic population, has peripheral neuropathy. In this exploratory, qualitative study conducted in Kuwait, 25 subjects with peripheral neuropathy took part in one-on-one, semi-structured interviews lasting 45-60 min. Interviews were transcribed, translated into English and coded using NVivo 12. Four individual patient journeys were mapped out in detail, then compared and condensed into a single process map. The remaining 21 interviews were then reviewed to ensure the final map represented all patient journeys. Participants reported similar healthcare pathways for their peripheral neuropathy and faced various difficulties including lack of psychological support, administrative issues (long waiting referral periods, loss of medical documents, shortage of specialists and lack of centralized electronic medical records) and inadequate medical care (shortage of new treatments and deficient follow-ups). Mapping the patient journey in Kuwait showed similar pharmacological treatment to UK guidelines, except that some medicines were unavailable. The map also indicated the need for an integrated referral approach, the use of technology for electronic medical recording and report transmission, alongside education on self-management, coping mechanisms and treatment options for people living with peripheral neuropathy.

Keywords: Kuwait healthcare; diabetes; patient experiences; peripheral neuropathic pain; process map.

Conflict of interest statement

The authors have no conflict of interests and the work was not supported or funded by any drug company.


Figure 1
Figure 1
A Process Map of People Living with Peripheral Neuropathy in Kuwait.3.1. Primary care clinic—the journey starts.

Similar articles

See all similar articles


    1. Sugimoto K., Yasujima M., Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 2008;14:953–961. doi: 10.2174/138161208784139774. - DOI - PubMed
    1. Singh V.P., Bali A., Singh N., Jaggi A.S. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. 2014;18:1–14. doi: 10.4196/kjpp.2014.18.1.1. - DOI - PMC - PubMed
    1. Jack M., Wright D. Role of advanced glycation end products and glyoxalase I in diabetic peripheral sensory neuropathy. Transl. Res. 2012;159:355–365. doi: 10.1016/j.trsl.2011.12.004. - DOI - PMC - PubMed
    1. England J.D., Gronseth G.S., Franklin G., Carter G.T., Kinsella L.J., Cohen J.A., Asbury A.K., Szigeti K., Lupski J.R., Latov N., et al. Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review) Neurology. 2009;72:185–192. doi: 10.1212/01.wnl.0000336370.51010.a1. - DOI - PubMed
    1. Watson J.C., Dyck P.J. Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management. Mayo Clin. Proc. 2015;90:940–951. doi: 10.1016/j.mayocp.2015.05.004. - DOI - PubMed